Search

Fagron

Aperta

SettoreSettore sanitario

21.25 -0.23

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

21.25

Massimo

21.25

Metriche Chiave

By Trading Economics

Entrata

46M

Vendite

476M

P/E

Media del settore

18.162

88.032

Rendimento da dividendi

1.65

Margine di Profitto

9.569

Dipendenti

3,989

EBITDA

87M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+20.59% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.65%

2.26%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.6B

Apertura precedente

21.48

Chiusura precedente

21.25

Notizie sul Sentiment di mercato

By Acuity

25%

75%

50 / 374 Classifica in Healthcare

Fagron Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 dic 2025, 22:20 UTC

I principali Market Mover

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 dic 2025, 17:31 UTC

I principali Market Mover

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 dic 2025, 16:30 UTC

I principali Market Mover

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 dic 2025, 15:19 UTC

I principali Market Mover

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 dic 2025, 15:17 UTC

I principali Market Mover

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 dic 2025, 14:37 UTC

I principali Market Mover

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

31 dic 2025, 21:13 UTC

Acquisizioni, Fusioni, Takeovers

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 dic 2025, 20:40 UTC

Discorsi di Mercato

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 dic 2025, 20:22 UTC

Discorsi di Mercato

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 dic 2025, 19:50 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 dic 2025, 19:31 UTC

Discorsi di Mercato

Precious Metals Cap Off Record Runs -- Market Talk

31 dic 2025, 18:50 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

31 dic 2025, 18:50 UTC

Discorsi di Mercato

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 dic 2025, 17:17 UTC

Discorsi di Mercato

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 dic 2025, 17:16 UTC

I principali Market Mover

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 dic 2025, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

31 dic 2025, 17:00 UTC

Acquisizioni, Fusioni, Takeovers

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 dic 2025, 15:57 UTC

Acquisizioni, Fusioni, Takeovers

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 dic 2025, 15:54 UTC

Discorsi di Mercato

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 dic 2025, 15:02 UTC

I principali Market Mover

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 dic 2025, 14:40 UTC

Acquisizioni, Fusioni, Takeovers

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 dic 2025, 14:20 UTC

Discorsi di Mercato

Crude Futures On Track to End the Year With Losses -- Market Talk

31 dic 2025, 13:46 UTC

Discorsi di Mercato

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 dic 2025, 13:01 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 dic 2025, 11:10 UTC

Discorsi di Mercato

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 dic 2025, 10:46 UTC

Discorsi di Mercato

Euro on Track For Strong Annual Performance -- Market Talk

31 dic 2025, 10:25 UTC

Discorsi di Mercato

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 dic 2025, 10:23 UTC

Discorsi di Mercato

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 dic 2025, 09:33 UTC

Discorsi di Mercato

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Fagron Previsione

Obiettivo di Prezzo

By TipRanks

20.59% in crescita

Previsioni per 12 mesi

Media 19.5 EUR  20.59%

Alto 19.5 EUR

Basso 19.5 EUR

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Fagron - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

50 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat